期刊文献+

硼替佐米对伊马替尼耐药细胞株K562的凋亡作用及机制 被引量:1

Effect of bortezomib in inducing apoptosis of imatinib-resistant K562 cells and the mechanism
下载PDF
导出
摘要 目的探讨硼替佐米对伊马替尼耐药细胞株K562(K562R)的诱导凋亡作用及机制。方法采用浓度梯增法建立耐伊马替尼K562细胞系。应用CCK-8法检测不同浓度硼替佐米分别作用K562和K562R细胞24 h、48 h后,对细胞的增殖抑制的效果。使用流式细胞术方法分别检测硼替佐米单独或联合伊马替尼作用于K562R细胞48 h后的细胞凋亡。应用Western blotting检测不同浓度硼替佐米作用K562R细胞48 h后,Mcl-1、Bcl-2、Bcr/Abl蛋白表达的异同。结果成功将对伊马替尼敏感的K562细胞诱导为K562R,耐药倍数为31.8;硼替佐米对K562及K562R细胞的增殖抑制呈浓度、时间依赖(P均<0.05);随着硼替佐米浓度增加,对K562R细胞的诱导凋亡作用增强,且硼替佐米与伊马替尼联合具有协同作用(P<0.05);硼替佐米可抑制K562R细胞Mcl-1,Bcr/Abl蛋白的表达,Bcl-2无变化。结论硼替佐米具有对K562R细胞的增殖抑制和诱导凋亡作用,其机制可能与下调K562R细胞Bcr/Abl和MCL-1的表达以及促进MCL-1发生切割有关。 Objective To investigate the effect of bortezomib in inducing apoptosis in imatinib-resistant K562 (K562R) cells and its possible mechanism. Methods K562 cells were cultured in gradient concentrations of imatinib for several months to generate imatinib-resistant K562 cells. The viability of K562R cells treated with bortezomib was measured using CCK-8 cell proliferation assay, and the cell apoptosis was analyzed by flow cytometry with annexin V/PI dual staining. Western blotting was used to detect the protein expressions of Mcl-1,Bcl-2 and Bcr/Abl. Results K562R cell line was successfully established, which showed 31.8 folds of imatinib resistance compared with the na?ve cells. Bortezomib treatment produced dose- and time-dependent inhibitory effect on the proliferation of both K562 cells and K562R cells and dose-dependently induced apoptosis in K562R cells. Combination of bortezomib with imatinib significantly enhanced the apoptosis of the cells. Western blotting showed that bortezomib treatment dose-dependently decreased the protein levels of both Mcl-1and Bcr/Abl in K562R cells without affecting bcl-2 protein expression. Conclusion Bortezomib can inhibit the proliferation of K562R cells and induce cell apoptosis possibly by down-regulating Mcl-1 and Bcr/Abl expression and enhancing Mcl-1 cleavage.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2017年第8期1136-1139,共4页 Journal of Southern Medical University
基金 广东省医学科学基金(A2014305)
关键词 硼替佐米 K562细胞 抗药性 伊马替尼 bortezomib K562 cells drug resistance imatinib
  • 相关文献

参考文献3

二级参考文献23

  • 1齐静,彭晖,顾振纶,梁中琴,杨纯正.伊马替尼耐药的K562细胞系的建立及其生物学特性研究[J].中华血液学杂志,2004,25(6):337-341. 被引量:20
  • 2Cohen MH,Johnson JR,Pazdur RUS.Food and drug administration drug approval summary:conversion of imatinib mesylate (STI571;Gleevec) tablets from accelerated approval to full approval.Clin Cancer Res,2005,11:12-19.
  • 3Druker BJ,Guilhot F,0' Brien SG,et al.Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.N Engl J Med,2006,355:2408-2417.
  • 4Gorre ME,Mohammed M,Ellwood K,et al.Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.Science,2001,293:876-880.
  • 5Azam M,Latek RR,Daley GQ.Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL Cell,2003,112:831-843.
  • 6Quintds-Cardama A,Kantarjian HM,Cortes JE.Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.Cancer Control,2009,16:122-131.
  • 7O'Connor OA,Wright J,Moskowitz C,et al.Phase Ⅱ clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.J Clin Oncol,2005,23:676-684.
  • 8Katodritou E,Verrou E,Gastari V,et al.Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone:Do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? Leuk Res,2008,32:1153-1156.
  • 9Baiz D,Pozzato G,Dapas B,et al.Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1,p21 and p27 levels.Biochimie,2009,91:373-382.
  • 10Milano A,Iaffaioli RV,Caponigro F.The proteasome:a worthwhile target for the treatment of solid tumours? Eur J Cancer,2007,43:1125-1133.

共引文献12

同被引文献8

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部